RELATED PARTIES	12 Months Ended
Dec. 31, 2017
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the years ended December 31, 2017, 2016 and 2015, the Company recognized net revenues of $37 million, $33 million and $30 million, respectively, associated with diagnostic information services provided to its equity method investees. As of December 31, 2017 and 2016, there was $3 million and $10 million, respectively, of accounts receivable from equity method investees related to such services. During the years ended December 31, 2017, 2016 and 2015, the Company recognized income of $16 million, $19 million and $31 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of December 31, 2017 and 2016, there was $7 million and $5 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of December 31, 2017 and 2016 included $1 million and $9 million, respectively, due to equity method investees.

RELATED PARTIES

The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the years ended December 31, 2017, 2016 and 2015, the Company recognized net revenues of $37 million, $33 million and $30 million, respectively, associated with diagnostic information services provided to its equity method investees. As of December 31, 2017 and 2016, there was $3 million and $10 million, respectively, of accounts receivable from equity method investees related to such services.

During the years ended December 31, 2017, 2016 and 2015, the Company recognized income of $16 million, $19 million and $31 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. As of December 31, 2017 and 2016, there was $7 million and $5 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of December 31, 2017 and 2016 included $1 million and $9 million, respectively, due to equity method investees.